Home
ARVN
ARVN News

Latest Arvinas Inc. (ARVN) News on January 22, 2025

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Motley Fool

a day ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

MT Newswires

12 days ago

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

GlobeNewswire

12 days ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Clinical Trials Arena

a month ago

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

Benzinga

a month ago

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

MT Newswires

a month ago

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

a month ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey

2 months ago

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

2 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

2 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Insider Monkey

2 months ago

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Arvinas Third Quarter 2024 Earnings: Beats Expectations

MT Newswires

3 months ago

UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

GuruFocus.com

3 months ago

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

MT Newswires

3 months ago

Arvinas' Q3 Net Loss Narrows, Revenue Rises

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Zacks

3 months ago

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

3 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

3 months ago

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Simply Wall St.

3 months ago

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Insider Monkey

3 months ago

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

GlobeNewswire

3 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

GlobeNewswire

3 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Simply Wall St.

4 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

GuruFocus.com

4 months ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Insider Monkey

5 months ago

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Arvinas to Participate in Upcoming Investor Conferences

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts

Simply Wall St.

6 months ago

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall St.

6 months ago

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

MT Newswires

6 months ago

Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating

MT Newswires

6 months ago

Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Zacks

6 months ago

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

6 months ago

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

GlobeNewswire

6 months ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Biotech Arvinas Stock Earns 82 RS Rating

Investor's Business Daily

6 months ago

Biotech Arvinas Stock Earns 82 RS Rating

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Zacks

6 months ago

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Milestone Pharmaceuticals Refreshes Board of Directors

GlobeNewswire

6 months ago

Milestone Pharmaceuticals Refreshes Board of Directors

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?

Insider Monkey

7 months ago

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?

MT Newswires

7 months ago

Arvinas Names Andrew Saik as Chief Financial Officer; Shares Rise After Hours

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

GlobeNewswire

7 months ago

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Zacks

7 months ago

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

GlobeNewswire

7 months ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

GlobeNewswire

7 months ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

CNW Group

7 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

CNW Group

7 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

7 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

7 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

7 months ago

New Zealand scraps plan to tax livestock burps, farts

Business Wire

7 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

7 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

7 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

GlobeNewswire

8 months ago

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope

Simply Wall St.

8 months ago

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope

MT Newswires

8 months ago

Sector Update: Health Care Stocks Steady Premarket Thursday

MT Newswires

8 months ago

Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity

MT Newswires

8 months ago

Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

GlobeNewswire

8 months ago

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

8 months ago

Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

GlobeNewswire

8 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

MT Newswires

8 months ago

Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Simply Wall St.

8 months ago

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

MT Newswires

8 months ago

Arvinas Shares Up After Q1 Net Loss Narrows

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Zacks

8 months ago

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Why Earnings Season Could Be Great for Arvinas (ARVN)

Zacks

9 months ago

Why Earnings Season Could Be Great for Arvinas (ARVN)

Arvinas to Present at Upcoming Investor Conferences

GlobeNewswire

9 months ago

Arvinas to Present at Upcoming Investor Conferences

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

9 months ago

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Zacks

9 months ago

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

9 months ago

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

GlobeNewswire

9 months ago

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Zacks

9 months ago

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Associated Press Finance

9 months ago

Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Investor's Business Daily

9 months ago

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Reuters

9 months ago

UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion

Reuters

9 months ago

Novartis licenses Arvinas' cancer drug for up to $1 billion

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

GlobeNewswire

9 months ago

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

Zacks

9 months ago

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire

10 months ago

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.

a year ago

Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?

Zacks

a year ago

Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a year ago

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week

Simply Wall St.

a year ago

Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week

Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?

What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?

Zacks

a year ago

What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?

Arvinas Announces Chief Financial Officer Transition

GlobeNewswire

a year ago

Arvinas Announces Chief Financial Officer Transition

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

GlobeNewswire

a year ago

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

GlobeNewswire

a year ago

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside

TipRanks

a year ago

Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside

Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

GlobeNewswire

a year ago

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

Zacks

a year ago

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?

Zacks

a year ago

Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?

Thomson Reuters StreetEvents

a year ago

Q4 2023 Sirius XM Holdings Inc Earnings Call

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

GlobeNewswire

a year ago

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

McGrath Sets Fourth Quarter 2023 Financial Results Date and Time

Business Wire

a year ago

McGrath Sets Fourth Quarter 2023 Financial Results Date and Time

Sirius XM (SIRI) Q4 2023 Earnings Call Transcript

Motley Fool

a year ago

Sirius XM (SIRI) Q4 2023 Earnings Call Transcript

Want $1,000 in Super-Safe Dividend Income in 2024? Invest $9,750 Into the Following 3 Ultra-High-Yield Stocks

Motley Fool

a year ago

Want $1,000 in Super-Safe Dividend Income in 2024? Invest $9,750 Into the Following 3 Ultra-High-Yield Stocks

Share on Social Networks: